Clinical Trials Browser

Withdrawn × Interventional × naxitamab × Clear all

NCT04909515 2022-09-01

Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.

Phase 2 Withdrawn

Neuroblastoma